"CZ - \u010Cesk\u00E1 republika" . . . "Cystic fibrosis and current treatment options"@en . "RIV/00064203:_____/13:10196238" . "http://www.praktickelekarenstvi.cz/artkey/lek-201306-0006_Cysticka_fibroza_a_soucasne_moznosti_lecby_pohledem_farmaceuta.php" . . . . . "I" . . "Cystick\u00E1 fibr\u00F3za (CF) je z\u00E1va\u017En\u00E9 d\u011Bdi\u010Dn\u00E9 onemocn\u011Bn\u00ED, kter\u00E9 p\u0159edstavuje zna\u010Dnou z\u00E1t\u011B\u017E pro pacienty i jejich rodiny a zkracuje \u017Eivot nemocn\u00FDch. Onemocn\u011Bn\u00ED se projevuje plicn\u00EDmi i mimoplicn\u00EDmi projevy, charakteristick\u00FDm p\u0159\u00EDznakem CF je vysok\u00E1 koncentrace chlorid\u016F v potu pacient\u016F. V plic\u00EDch doch\u00E1z\u00ED k mukost\u00E1ze, obstrukci a chronick\u00E9 infekci. L\u00E9\u010Dba plicn\u00EDch projev\u016F m\u00E1 z\u00E1sadn\u00ED vliv na kvalitu a d\u00E9lku \u017Eivota pacient\u016F. Ta spo\u010D\u00EDv\u00E1 zejm\u00E9na v p\u00E9\u010Di o dobrou pr\u016Fchodnost d\u00FDchac\u00EDch cest prost\u0159ednictv\u00EDm respira\u010Dn\u00ED fyzioterapie a l\u00E9k\u016F sni\u017Euj\u00EDc\u00EDch viskozitu hlenu v d\u00FDchac\u00EDch cest\u00E1ch a v l\u00E9\u010Db\u011B z\u00E1va\u017En\u00FDch plicn\u00EDch infekc\u00ED antibiotiky. V tr\u00E1vic\u00EDm traktu doch\u00E1z\u00ED k poru\u0161e exokrinn\u00ED funkce pankreatu, v d\u016Fsledku toho nen\u00ED mo\u017En\u00E9 vst\u0159eb\u00E1v\u00E1n\u00ED tuk\u016F z potravy a doch\u00E1z\u00ED k podv\u00FD\u017Eiv\u011B. L\u00E9\u010Dba mimoplicn\u00EDch projev\u016F spo\u010D\u00EDv\u00E1 v substituci pankreatick\u00FDch enzym\u016F, d\u016Frazu na v\u00FD\u017Eivu pacient\u016F, l\u00E9\u010Db\u011B hepatopatie a ve v\u010Dasn\u00E9 l\u00E9\u010Db\u011B komplikac\u00ED, zvl\u00E1\u0161t\u011B diabetu, osteopor\u00F3zy, st\u0159evn\u00ED obstrukce a dal\u0161\u00EDch (1-4). Jako klinick\u00E1 jednotka je toto onemocn\u011Bn\u00ED zn\u00E1mo ji\u017E od 40. let 20. stolet\u00ED, p\u016Fvodn\u011B s jednozna\u010Dn\u011B fat\u00E1ln\u00ED diagn\u00F3zou ji\u017E v prvn\u00EDm roce \u017Eivota. D\u00EDky zlep\u0161en\u00ED diagnostick\u00FDch metod a intenzivn\u00EDm l\u00E9\u010Debn\u00FDm postup\u016Fm se nyn\u00ED a\u017E 50 % pacient\u016F do\u017E\u00EDv\u00E1 4. dek\u00E1dy \u017Eivota (4, 5). C\u00EDlem tohoto sd\u011Blen\u00ED je shrnout sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby CF s ohledem na zapojen\u00ED farmaceuta do p\u00E9\u010De o pacienty s CF." . "67652" . . . "Cystic fibrosis (CF) is a serious hereditary disease, which represents a significant burden for patients and their families, and shortens the life of patients. The disease manifests with pulmonary and extrapulmonary manifestations, a characteristic symptom of CF is a high concentration of chloride in the sweat of patients. Mucostasis, obstruction and chronic infection occur in the lungs. Treatment of pulmonary manifestations has a major impact on the quality and length of the life of patients. This is especially good care of the airway through respiratory physiotherapy and drugs that reduce the viscosity of mucus in the airways and in the treatment of serious lung infections with antibiotics. In the digestive tract CF leads to failure of exocrine pancreatic function, consequently the absorption of fat from food is not possible and it leads to malnutrition. Treatment of extrapulmonary manifestations includes substitution of pancreatic enzymes, especially nutrition of patients, treatment of liver disease and early treatment of complications such as diabetes, osteoporosis, intestinal obstruction, and others. As a clinical entity, this disease is known since the 40th of last century, originally a clearly fatal diagnosis in the first year of life. Thanks to improved diagnostic methods and intense treatments are now up to 50% of patients live for the fourth decades of life. The purpose of this article is to show the current CF treatment options with regard to the involvement of pharmacist in the care of patients with CF."@en . . "Cystick\u00E1 fibr\u00F3za a sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby pohledem farmaceuta"@cs . "RIV/00064203:_____/13:10196238!RIV14-MZ0-00064203" . "Cystick\u00E1 fibr\u00F3za (CF) je z\u00E1va\u017En\u00E9 d\u011Bdi\u010Dn\u00E9 onemocn\u011Bn\u00ED, kter\u00E9 p\u0159edstavuje zna\u010Dnou z\u00E1t\u011B\u017E pro pacienty i jejich rodiny a zkracuje \u017Eivot nemocn\u00FDch. Onemocn\u011Bn\u00ED se projevuje plicn\u00EDmi i mimoplicn\u00EDmi projevy, charakteristick\u00FDm p\u0159\u00EDznakem CF je vysok\u00E1 koncentrace chlorid\u016F v potu pacient\u016F. V plic\u00EDch doch\u00E1z\u00ED k mukost\u00E1ze, obstrukci a chronick\u00E9 infekci. L\u00E9\u010Dba plicn\u00EDch projev\u016F m\u00E1 z\u00E1sadn\u00ED vliv na kvalitu a d\u00E9lku \u017Eivota pacient\u016F. Ta spo\u010D\u00EDv\u00E1 zejm\u00E9na v p\u00E9\u010Di o dobrou pr\u016Fchodnost d\u00FDchac\u00EDch cest prost\u0159ednictv\u00EDm respira\u010Dn\u00ED fyzioterapie a l\u00E9k\u016F sni\u017Euj\u00EDc\u00EDch viskozitu hlenu v d\u00FDchac\u00EDch cest\u00E1ch a v l\u00E9\u010Db\u011B z\u00E1va\u017En\u00FDch plicn\u00EDch infekc\u00ED antibiotiky. V tr\u00E1vic\u00EDm traktu doch\u00E1z\u00ED k poru\u0161e exokrinn\u00ED funkce pankreatu, v d\u016Fsledku toho nen\u00ED mo\u017En\u00E9 vst\u0159eb\u00E1v\u00E1n\u00ED tuk\u016F z potravy a doch\u00E1z\u00ED k podv\u00FD\u017Eiv\u011B. L\u00E9\u010Dba mimoplicn\u00EDch projev\u016F spo\u010D\u00EDv\u00E1 v substituci pankreatick\u00FDch enzym\u016F, d\u016Frazu na v\u00FD\u017Eivu pacient\u016F, l\u00E9\u010Db\u011B hepatopatie a ve v\u010Dasn\u00E9 l\u00E9\u010Db\u011B komplikac\u00ED, zvl\u00E1\u0161t\u011B diabetu, osteopor\u00F3zy, st\u0159evn\u00ED obstrukce a dal\u0161\u00EDch (1-4). Jako klinick\u00E1 jednotka je toto onemocn\u011Bn\u00ED zn\u00E1mo ji\u017E od 40. let 20. stolet\u00ED, p\u016Fvodn\u011B s jednozna\u010Dn\u011B fat\u00E1ln\u00ED diagn\u00F3zou ji\u017E v prvn\u00EDm roce \u017Eivota. D\u00EDky zlep\u0161en\u00ED diagnostick\u00FDch metod a intenzivn\u00EDm l\u00E9\u010Debn\u00FDm postup\u016Fm se nyn\u00ED a\u017E 50 % pacient\u016F do\u017E\u00EDv\u00E1 4. dek\u00E1dy \u017Eivota (4, 5). C\u00EDlem tohoto sd\u011Blen\u00ED je shrnout sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby CF s ohledem na zapojen\u00ED farmaceuta do p\u00E9\u010De o pacienty s CF."@cs . "Cystick\u00E1 fibr\u00F3za a sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby pohledem farmaceuta"@cs . . . . "Praktick\u00E9 l\u00E9k\u00E1renstv\u00ED" . "6"^^ . "1803-5329" . "nutrition; cystic fibrosis, exacerbation, respiratory physiotherapy, pancreatic insufficiency"@en . "Tajovsk\u00E1, Eli\u0161ka" . "1"^^ . . "6" . . "1"^^ . "Cystick\u00E1 fibr\u00F3za a sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby pohledem farmaceuta" . . . "[A27467C4DD33]" . "9" . "Cystick\u00E1 fibr\u00F3za a sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby pohledem farmaceuta" . "Cystic fibrosis and current treatment options"@en .